This inactivation of STING represents a novel immune evasion strategy, particularly in lung adenocarcinomas harboring co-mutations in KRAS and STK11, where it contributes to resistance against host immune responses [48,49,50]. The gene discussed is STK11; the disease is lung adenocarcinoma.